The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial
Open accessAbstract
BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In this randomized controlled clinical trial, we evaluated the efficacy and safety of saroglitazar in patients with NAFLD/NASH. APPROACH AND RESULTS: were randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. The primary efficacy endpoint was percentage change from baseline in ALT levels at week 16. Liver fat content (LFC) was assessed by MRI proton density fat fraction. The least-squares mean percent change from baseline in ALT at week 16 was -25.5% (5.8), -27.7% (5.9), and -45.8% (5.7), with saroglitazar 1 mg, 2 mg, and 4 mg, respectively, versus 3.4% (5.6) in placebo (P < 0.001 for all). Compared with placebo, saroglitazar 4 mg improved LFC (4.1% [5.9] vs. -19.7% [5.6]), adiponectin (-0.3 μg/mL [0.3] vs. 1.3 μg/mL [0.3]), homeostatic model assessment-insulin resistance (-1.3 [1.8] vs. -6.3 [1.7]), and triglycerides (-5.3 mg/dL [10.7] vs. -68.7 mg/dL [10.3]) (P < 0.05 for all). Saroglitazar 4 mg also improved lipoprotein particle composition and size and reduced lipotoxic lipid species. Saroglitazar was well-tolerated. A mean weight gain of 1.5 kg was observed with saroglitazar 4 mg versus 0.3 kg with placebo (P = 0.27). CONCLUSIONS: Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two Phase II trials have investigated the effects of saroglitazar, a PPARα/γ agonist, and found improvement of ALT and hepatic fat (measured via MRI‐PDFF) [57] but no improvement of NAS (primary endpoint: delta change of NAS from baseline to Week 24 biopsy) [58].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“Saroglitazar, a dual PPAR a / c agonist has been shown to improve insulin resistance, liver steatosis and liver enzymes 426 and is approved in India for the treatment of T2D and MASH.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [426]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This lack of basic information may have confounded true treatment effects and results in serious difficulties concerning cross-trial comparisons [240].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [240]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citation2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationVernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli‐Labate, A. M., Bianchi, G. P., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,570
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,304
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–379 of 379
Rhodium‐Catalyzed N‐Arylation Addition of Arylboronic Acids to Ketimines
Qian, X., & Sun, X. (2024) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202400208 · Cited by 2
Paniz, G. R., Arroyo-Mercado, F. M. M., Ling, C. L., Choi, E. E., Snow, H. E., Rakov, N. E., & Castillo, E. F. (2021) · medRxiv · doi:10.1101/2021.05.27.21257690 · Cited by 2
Recurrent NAFLD post-LT: Sisyphus’ boulder or Proteus’ parable?
Odenwald, M. A., & Rinella, M. E. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000161 · Cited by 2
Tan, W., Deng, J., Qi, L., & Tan, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1467950 · Cited by 2
Shah, N. A., Paul, S., Parveen, S., Bhat, M. H., Ali, I., & Kadla, S. A. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20251836 · Cited by 1
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 1
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Berg, E. V., Moftah, S., Yuzbashian, E., & Chan, C. B. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.09.020 · Cited by 1
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Tang, Y., Xie, B., Zhang, Y., Li, S., Liu, H., Wang, B., Ye, X., Zhou, H., & Zhou, J. H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157749 · Cited by 1
Rashid, S. A., Suriyan, A., Azam, M. B., Balasubramanian, R., Maideen, N. M. P., Chidambaram, K., & Amirthalingam, P. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2787-1205 · Cited by 1
Zhang, S.-J., Xu, K., Zhu, F., Chen, J.-G., Zhang, Y., Teng, Y.-Q., & Shen, F.-F. (2026) · Physiological Research · doi:10.33549/physiolres.935711 · Cited by 1
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Tsutsumi, T., Tang, N. S. Y., Ng, C. H., Suzuki, H., Syn, N. L., Sasikumar, N. A., Ho, G. J. K., Chua, D., Tioh, J. K., Pramotedham, T., et al. (2026) · Med · doi:10.1016/j.medj.2026.101077 · Cited by 1
Self-citationBhagat, N., De, A., Duseja, A. K., Ganesh, C. P., Kumar, M., Mehta, M., Taneja, S., Sahni, N., & Singh, V. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_2953_2025 · Cited by 1
Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target
Noor, S., Tian, Y., & Su, W. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1912237 · Cited by 1
Azologs of the Fatty Acid Mimetic Drug Cinalukast Enable Light‐Induced PPARα Activation
Sai, M., van Herwijnen, N., & Merk, D. (2024) · ChemMedChem · doi:10.1002/cmdc.202400327 · Cited by 1
Sinha, B., Ghosal, S., & Datta, D. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_10_24 · Cited by 1
Treatment of NAFLD: Diet, Physical Activity, and Potential Pharmacological Options
Śliz, J., Popławska, N. A., Skorupska, M., Czeczotka, M. J., Woźniak, K., & Martka, M. M. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52219 · Cited by 1
Wen, Y., Li, J., Mukama, O., Huang, R., Deng, S., & Li, Z. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.03.007 · Cited by 1
Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.03.007 · Cited by 1
Puri, P. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.002
Ruolo dei farmaci non antidiabete nel trattamento della NAFLD
Maurizio Russello, M. L. A. (2021) · il Diabete · doi:10.30682/ildia2102c
II. Nonalcoholic Fatty Liver Disease NAFLD as an Harbinger of Cancer: Implications for India
(2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.003
Liu, Y., Xu, T., Wang, X., Lu, M., Yuan, M., Gong, M., Li, Q., Xia, Y., Yu, Z. H., & Xu, B. (2022) · Research Square · doi:10.21203/rs.3.rs-2349051/v1
Durga, D. R., Mounika, N., Mudimala, P., & Adela, R. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-022-01244-5
Metabolic-associated fatty liver disease: pharmacological management
Shi, Y., & Fan, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00010-0
Muzica, C. M., Trifan, A. V., Zenovia, S., Gîrleanu, I., Cojocariu, C., & Stanciu, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_21
Li, Y., Lv, M., Shen, M., Gu, X., Zhang, L., Liu, X., Chen, J., Gong, L., & Zuo, Z. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2256867
Amigó, N., & Betes, P. O. (2023) · Springer eBooks · doi:10.1007/978-981-99-5162-8_12
Saravanan, T., Shanmugapriya, S., Thomas, E., & Karthika, P. (2023) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x231213486
Pang, B., Huang, N., Huang, X., Li, X., Xiong, W., Kong, B., & Yao, Y. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.12.13
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Lin, K.-H., Amigó, N., Ortiz, P., Alonso, C., Smolensky, A. V., Parmar, D., Chalasani, N., & Gawrieh, S. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.04.004
Self-citationNonalcoholic fatty liver disease is a risk factor for cardiovascular disease
Li, Q. I. N., JunRu, W. U., YuQing, L. I. U., YingXuan, G. O. N. G., & JingJing, C. A. I. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0098
Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
Abdel-Samiee, M., Ibrahim, E. S., Kohla, M., Abdelsameea, E., & Salama, M. (2024) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v15.i6.97381
The SVIN-Trial—Just Another Brick in the Wall?
Mehtani, R. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102449
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 2
Lin, K.-H., Amigó, N., Ortiz, P., Alonso, C., Smolensky, A. V., Parmar, D., Chalasani, N., & Gawrieh, S. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100723
Self-citationZhao, Y., Bi, Y., Zhang, W., Li, K., Lin, G., Lin, X., Chen, Y., Jiang, X., Zhao, X., & Fan, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5163154
NASH Cirrhosis: A Systematic Review of Phase 2B Trials
Singh, B., Ramanan, S. P., Singh, W., Kaur, G., Grover, P., & Sridhar, N. (2025) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2025.154014
Peroxisome proliferator-activated receptors in metabolic and renal health: a comprehensive review
Vahora, N., Yathindra, M. R., James, D. M., Sharma, R., Panvalkar, A. S., Shyam, G., & Swathi, N. L. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20252817
Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Zeb, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00023-8
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Roy, A., Chakraborty, S., Jajodia, S., Goenka, U., Tewari, A., Sonthalia, N., Ghoshal, U. C., & Goenka, M. K. (2025) · Cureus · doi:10.7759/cureus.92313
Kumar, G. V., Mishra, A., & Singh, B. (2025) · Research Square · doi:10.21203/rs.3.rs-7691361/v1
Hu, X., Fan, J., Ma, Q., Han, L., Cao, Z., Xu, C., Luan, J., Jing, G., Nan, Y., Wu, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19801441
Meher, D., DAS, S., Choudhury, A. K., Sahoo, D., Sahu, S. K., Agarwal, V., Prusty, B., Das, B. K., Chappalagavi, A. S., Gupta, S., et al. (2025) · Cureus · doi:10.7759/cureus.100002
A flow cytometry-based assay system for the in vitro screening of anti-steatotic compounds
Deshmukh, K., Malladi, N., & Banerjee, S. K. (2026) · In vitro models · doi:10.1007/s44164-026-00110-4
Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease
Li, X., Zhang, J., Wei, B., & Tong, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1775516
Bong, S. H. S., Teh, K. K., & Wong, V. W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0125
Pathophysiologie der mit metabolischer Dysfunktion assoziierten steatotischen Lebererkrankung
Kantartzis, K. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01459-6
Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
Carbinatti, T. (2024) · theses.fr (ABES) · doi:10.70675/5d147ab4zad37z4f6bzac51z32a08efeaa51
Rôle de FAT10 dans la sénescence des hépatocytes et le développement de la NASH
Bernard, L. (2023) · theses.fr (ABES) · doi:10.70675/793b0b93z9794z42d4zb8dfz5f3d68268a9b
Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies
Munda, B., Bhutia, C., Deepti, & Khatri, M. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.011
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
Yang, Y., Zhang, F., Peng, Z., Wu, Y., Li, L., Shen, Z., Ye, Q., Yue, J., & Na, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.029
Jagadeesha, A., Bhattacharya, S., SHRIVASTAVA, A., Samajdar, S. S., Gunjan, G., Bhardwaj, S., & TELANG, S. (2026) · Cureus · doi:10.7759/cureus.111328
Zhou, H., Yang, J., Wu, W., Wei, S., ZHAO, Y., & Li, C. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2695704
Romeo, M., Basile, C., Imperatore, A., Mozzi, G., Nardo, F. D., Napolitano, C., Vaia, P., Puorto, L. D., Indipendente, M., Dallio, M., et al. (2026) · Cells · doi:10.3390/cells15141292 · Cited by 1
Zhu, S., Yang, F., Lu, H., Jiang, J., & He, W. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1843719
Xiu, H., Li, T., Wen, J., Li, Z. B., Wu, J., Fu, X., Zhang, C., Yang, Z., Yao, X., & Xu, Z. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70416
Ahmad, P., Faruqui, T., Waiz, M., Mahdi, A. A., & Khan, M. S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100540
Kehar, M., Ramji, A. S., Swain, M., Singer, A. G., IVERS, N., Schaufert, W., Betel, M., Dasgupta, K., Sebastiani, G., & Patel, K. (2026) · Canadian Liver Journal · doi:10.3138/canlivj-2026-9-3-guidelines
Das, B. K., Das, S., Meher, D., Choudhury, A. K., Padhee, S., Sahu, S. K., Sahoo, D., Prusty, B., & Agarwal, V. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_848_25
The monoacylglycerol acyltransferase 2 inhibitor VB-85387 reduces MASLD
Gallo-Ebert, C., Wayne, J., Brown, A., & Nickels, J. T. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101137
The Cardio-Renal-Hepatic Axis in MASLD. Role of BDNF, NGF, and Metabolic Cross-Talk
Taylor, L. C., Adenawoola, M. I., Wingfield, C. B., Nadolski, M. K., & Stec, D. E. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01388-1
Akhand, M. S., Noor-E-Alam, S. M., Rahim, M. A., Karim, R., Hasan, M. R., Karmakar, D., Mondal, D. K., Sopan, N. T., Jalal, J. B., Arafat, M. A., et al. (2026) · Journal of Indian System of Medicine · doi:10.5005/jism-11051-0050
Rewiring the psoriasis–metabolism axis: therapeutic potential of saroglitazar beyond PPAR modulation
Vashisht, K., kumar, D. H., Rana, S., Ashawat, M. S., & Kushawaha, S. K. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02413-0
Lipotoxicity in MAFLD/MASH: cellular mechanisms and targetable nodes
Tawai, J., Zhou, K., & Xiong, J. (2026) · Targetome · doi:10.48130/targetome-0026-0047
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Samala, N. R., González‐González, J. G., Jenders, R. A., Sarkar, M. A., Reza, R., Rodas, F. V., Kipnes, M. S., Gonzalez, E. M., Huddleston, H. G., Momin, T., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001862
Self-citationQian, Y., Lai, L., Zhang, Y., Meng, Y., Song, Z., Huang, B., Song, G., Bo, S., & Yang, W. (2026) · Advanced Science · doi:10.1002/advs.78004
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Melnikova, I., Karabanovich, G., Dušek, J., Ambrož, M., Laštůvková, H., Smutný, T., Bajnokova, M., Kamaraj, R., Salam, R., Reguli, A., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119458
Metadata
- Authors
- Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N.
- Affiliations
- Indiana University School of Medicine (US)
- Cedars-Sinai Medical Center (US)
- Texas Liver Institute (US)
- Catalina Research Institute (US)
- Marion General Hospital (US)
- University of Florida Health (US)
- Liver Institute Northwest (US)
- Beth Israel Deaconess Medical Center (US)
- University of Miami (US)
- Zydus Discovery DMCC,Dubai,UAE
- Zydus Lifesciences Limited (India) (IN)
- Corresponding author
- Chalasani, Naga
- ORCID
- Venue
- Hepatology
- Published
- 2021-07-19
- Volume
- 74
- Issue
- 4
- Pages
- 1809-1824
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3149930516
- Cited by
- 379
- References
- 48
- Citations by year
- 2026: 46 · 2025: 82 · 2024: 82 · 2023: 87 · 2022: 57 · 2021: 25
- FWCI
- 45.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Celgene
- Novo Nordisk
- Allergan
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- saroglitazar, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, PPAR alpha/gamma agonist, insulin resistance, atherogenic dyslipidemia, liver fat, ALT, adiponectin, triglycerides, drug safety and tolerability, weight gain, PPARγ antagonist, PPARα
- MeSH terms
- Adipose Tissue, Adult, Alanine Transaminase, Alkaline Phosphatase, Aspartate Aminotransferases, Cholesterol, Double-Blind Method, Female, gamma-Glutamyltransferase, Humans, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Phenylpropionates, Pyrroles, Triglycerides, Cholesterol, VLDL, PPAR alpha, PPAR gamma, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
